Molecular Partners Ag (MOLN) EBIT Margin (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly EBIT Margin of 97.86% for Q1 2026, up 1306.0% year-on-year from 6.96% in Q1 2025, and down 100.07% on a QoQ basis from 132831.87% in Q4 2025.
Molecular Partners Ag (MOLN) EBIT Margin (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EBIT Margin for 7 consecutive years, with 97.86% the latest figure, recorded in Q1 2026.
- Quarterly EBIT Margin rose 1306.0% year-over-year to 97.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2595731.22% (up 259572981.0% YoY) and the FY2025 annual result came in at 100041308.09%, down 10004008375.0% from the prior year.
- EBIT Margin fell to 97.86% in Q1 2026 per MOLN's latest filing, from 132831.87% in the prior quarter.
- Over the last five years, EBIT Margin for MOLN reached as high as 132831.87% in Q4 2025 and fell as low as 1030045132.17% in Q2 2024.
- A 5-year average of 60589354.9% and a median of 97.86% in 2026 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2024 — EBIT Margin sank 2000000000 bps — and 2025, when it soared 2000000000 bps.
- Year by year, EBIT Margin stood at 82.54% in 2022, then slumped by 1113 bps to 835.85% in 2023, then jumped by 100 bps to 1.1% in 2024, then jumped by 12110523 bps to 132831.87% in 2025, then sank by 100 bps to 97.86% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 97.86%, 132831.87%, and 99.57% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -97.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.86% |
| Dec 31, 2025 | 132,831.87% |
| Sep 30, 2025 | -99.57% |
| Jun 30, 2025 | -100,000.00% |
| Mar 31, 2025 | -110.92% |
| Dec 31, 2024 | 1.10% |
| Sep 30, 2024 | -2,780.76% |
| Jun 30, 2024 | -1,030,045,132.17% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | -835.85% |
| Sep 30, 2023 | -450.61% |
| Jun 30, 2023 | -3,827.23% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 82.54% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 1,297.44% |
| Mar 31, 2022 | 88.77% |
| Dec 31, 2021 | -648.27% |
| Sep 30, 2021 | -352.11% |
| Jun 30, 2021 | 3.47% |